Nasus Pharma announces data demonstrating in vitro efficacy of Taffix intranasal antiviral spray against the new highly infectious Omicron variant of SARS-CoV-2
Taffix® blocks the Omicron Variant of SARS-CoV-2 in addition to the Alpha (UK) and Beta (South African) and Delta Variants Tel Aviv , Israel January